Category - Developments

Developments

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...

October 21, 2024

Developments

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...

October 21, 2024

Developments

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...

October 21, 2024

Developments

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...

October 17, 2024

Developments

Celularity expands portfolio acquiring Rebound from Sequence

Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...

October 17, 2024

Developments

Conavi Medical moves stock listing to TSXV following reverse takeover of Titan Medical

After completing its reverse takeover of Titan Medical on October 11th, Conavi Medical has completed its plan to voluntarily delist from the TSX and subsequently list on the TSX Venture Exchange (TSXV). Trading of...

October 16, 2024

Developments

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...

October 16, 2024

Developments

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Theriva Biologics (NYSE American:TOVX) has announced that the European Commission (EC) has adopted the European Medicines Agency’s (EMA) recommendation to grant orphan medicinal product designation to its lead...

October 16, 2024

Developments

Ripple and Glaukos ink evaluation and licensing agreements

Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation (NYSE:GKOS), enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release...

October 15, 2024

Developments

Conavi completes go-public transaction

Conavi Medical has completed its reverse takeover of Titan Medical (TSX:TMD; OTC:TMDIF). The combined company (the Resulting Issuer), which will voluntarily delist from the TSX on or about October 15, 2024, and...

October 11, 2024

Category - Developments

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Celularity expands portfolio acquiring Rebound from Sequence

Conavi Medical moves stock listing to TSXV following reverse takeover of Titan Medical

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Ripple and Glaukos ink evaluation and licensing agreements

Conavi completes go-public transaction

General

More